Literature DB >> 34351736

One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling.

Chong Ou1, Chao Li1, Roushu Zhang1, Qiang Yang1, Guanghui Zong1, Yuanwei Dai1, Rebecca L Francis2, Stylianos Bournazos2, Jeffrey V Ravetch2, Lai-Xi Wang1.   

Abstract

Antibody-drug conjugates (ADCs) are an important class of therapeutic agents that harness the highly specific antigen targeting property of antibodies to deliver toxic drugs for targeted cell killing. Site-specific conjugation methods are highly desirable for constructing homogeneous ADCs that possess a well-defined antibody-to-drug ratio, stability, ideal pharmacological profile, and optimal therapeutic index. We report here a facile synthesis of functionalized glycan oxazolines from free sialoglycans that are key donor substrates for enzymatic Fc glycan remodeling and the application of an efficient endoglycosidase mutant (Endo-S2 D184M) for site-specific glycan transfer to construct homogeneous ADCs. We found that by a sequential use of two coupling reagents under optimized conditions, free sialoglycans could be efficiently converted to selectively functionalized glycan oxazolines carrying azide-, cyclopropene-, and norbornene-tags, respectively, in excellent yield and in a simple one-pot manner. We further demonstrated that the recently reported Endo-S2 D184 M mutant was highly efficient for Fc glycan remodeling with the selectively modified glycan oxazolines to introduce tags into an antibody, which required a significantly smaller amount of glycan oxazolines and a much shorter reaction time than that of the Endo-S D233Q-catalyzed reaction, thus minimizing the side reactions. Finally homogeneous ADCs were constructed with three different click reactions. The resulting ADCs showed excellent serum stability, and in vitro cytotoxicity assays indicated that all the three ADCs generated from the distinct click reactions possessed potent and comparable cytotoxicity for targeted cancer cell killing.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34351736      PMCID: PMC8857982          DOI: 10.1021/acs.bioconjchem.1c00314

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   6.069


  47 in total

1.  Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.

Authors:  A C Stan; D L Radu; S Casares; C A Bona; T D Brumeanu
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 2.  Antibody Glycoengineering and Homogeneous Antibody-Drug Conjugate Preparation.

Authors:  Shino Manabe; Yoshiki Yamaguchi
Journal:  Chem Rec       Date:  2021-04-22       Impact factor: 6.771

3.  Site-Specific Bioconjugation and Multi-Bioorthogonal Labeling via Rapid Formation of a Boron-Nitrogen Heterocycle.

Authors:  Tak Ian Chio; Han Gu; Kamalika Mukherjee; L Nathan Tumey; Susan L Bane
Journal:  Bioconjug Chem       Date:  2019-05-03       Impact factor: 4.774

Review 4.  Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates.

Authors:  Hendrik Schneider; Lukas Deweid; Olga Avrutina; Harald Kolmar
Journal:  Anal Biochem       Date:  2020-02-05       Impact factor: 3.365

5.  Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates.

Authors:  Feng Tang; Lai-Xi Wang; Wei Huang
Journal:  Nat Protoc       Date:  2017-07-27       Impact factor: 13.491

6.  Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.

Authors:  Frank Loganzo; Xingzhi Tan; Matthew Sung; Guixian Jin; Jeremy S Myers; Eugene Melamud; Fang Wang; Veronica Diesl; Maximillian T Follettie; Sylvia Musto; My-Hanh Lam; William Hu; Manoj B Charati; Kiran Khandke; Kenny Sung Kyoo Kim; Mike Cinque; Judy Lucas; Edmund Graziani; Andreas Maderna; Christopher J O'Donnell; Kim T Arndt; Hans-Peter Gerber
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

7.  Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling.

Authors:  Tiezheng Li; Xin Tong; Qiang Yang; John P Giddens; Lai-Xi Wang
Journal:  J Biol Chem       Date:  2016-06-10       Impact factor: 5.157

8.  Site-specific antibody-drug conjugation through glycoengineering.

Authors:  Qun Zhou; James E Stefano; Charlene Manning; Josephine Kyazike; Bo Chen; Diego A Gianolio; Anna Park; Michelle Busch; Julie Bird; Xiaoyang Zheng; Helene Simonds-Mannes; Jennifer Kim; Rick C Gregory; Robert J Miller; William H Brondyk; Pradeep K Dhal; Clark Q Pan
Journal:  Bioconjug Chem       Date:  2014-02-28       Impact factor: 4.774

Review 9.  Unlocking the potential of antibody-drug conjugates for cancer therapy.

Authors:  Joshua Z Drago; Shanu Modi; Sarat Chandarlapaty
Journal:  Nat Rev Clin Oncol       Date:  2021-02-08       Impact factor: 65.011

10.  Generation of efficient mutants of endoglycosidase from Streptococcus pyogenes and their application in a novel one-pot transglycosylation reaction for antibody modification.

Authors:  Mitsuhiro Iwamoto; Yukiko Sekiguchi; Kensuke Nakamura; Yoshirou Kawaguchi; Takeshi Honda; Jun Hasegawa
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

View more
  5 in total

1.  Site-selective sulfation of N-glycans by human GlcNAc-6-O-sulfotransferase 1 (CHST2) and chemoenzymatic synthesis of sulfated antibody glycoforms.

Authors:  Kun Huang; Chao Li; Guanghui Zong; Sunaina Kiran Prabhu; Digantkumar G Chapla; Kelley W Moremen; Lai-Xi Wang
Journal:  Bioorg Chem       Date:  2022-08-01       Impact factor: 5.307

2.  Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation.

Authors:  Xiao Zhang; Chong Ou; Huiying Liu; Lai-Xi Wang
Journal:  Bioconjug Chem       Date:  2022-05-11       Impact factor: 6.069

3.  Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.

Authors:  Xiao Zhang; Huiying Liu; Jia He; Chong Ou; Thomas C Donahue; Musleh M Muthana; Lishan Su; Lai-Xi Wang
Journal:  ACS Chem Biol       Date:  2022-03-22       Impact factor: 4.634

4.  Synthetic Antibody-Rhamnose Cluster Conjugates Show Potent Complement-Dependent Cell Killing by Recruiting Natural Antibodies.

Authors:  Chong Ou; Sunaina Kiran Prabhu; Xiao Zhang; Guanghui Zong; Qiang Yang; Lai-Xi Wang
Journal:  Chemistry       Date:  2022-02-21       Impact factor: 5.236

5.  General and Robust Chemoenzymatic Method for Glycan-Mediated Site-Specific Labeling and Conjugation of Antibodies: Facile Synthesis of Homogeneous Antibody-Drug Conjugates.

Authors:  Xiao Zhang; Chong Ou; Huiying Liu; Sunaina Kiran Prabhu; Chao Li; Qiang Yang; Lai-Xi Wang
Journal:  ACS Chem Biol       Date:  2021-09-27       Impact factor: 5.100

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.